Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis | Zendy

Monique E. Cho | Zendy; David C. Smith | Zendy; Mary H. Branton | Zendy; Scott Penzak | Zendy; Jeffrey B. Kopp | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

Author(s) -

Monique E. Cho,

David C. Smith,

Mary H. Branton,

Scott Penzak,

Jeffrey B. Kopp

Publication year - 2007

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01050207

Subject(s) - pirfenidone , medicine , interquartile range , renal function , adverse effect , urology , idiopathic pulmonary fibrosis , gastroenterology , glomerulosclerosis , surgery , kidney , proteinuria , lung

Pirfenidone is an orally available antifibrotic agent that has shown benefit in animal models of pulmonary and renal fibrosis and in clinical trials of pulmonary fibrosis, multiple sclerosis, and hepatic cirrhosis. Our objective was to determine whether pirfenidone slows the loss of renal function in focal segmental glomerulosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research